Format
Sort by
Items per page

Send to

Choose Destination

Best matches for phytocannabinoids:

Molecular Pharmacology of Phytocannabinoids. Turner SE et al. Prog Chem Org Nat Prod. (2017)

Molecular Targets of the Phytocannabinoids: A Complex Picture. Morales P et al. Prog Chem Org Nat Prod. (2017)

Phytocannabinoids: a unified critical inventory. Hanuš LO et al. Nat Prod Rep. (2016)

Search results

Items: 1 to 20 of 251

1.

Δ-9-Tetrahydrocannabinol and Cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors.

Szkudlarek HJ, Desai SJ, Renard J, Pereira B, Norris C, Jobson CEL, Rajakumar N, Allman BL, Laviolette SR.

Neuropsychopharmacology. 2018 Nov 27. doi: 10.1038/s41386-018-0282-7. [Epub ahead of print]

PMID:
30538288
2.

Optimizing Hemp Fiber Production for High Performance Composite Applications.

Musio S, Müssig J, Amaducci S.

Front Plant Sci. 2018 Nov 23;9:1702. doi: 10.3389/fpls.2018.01702. eCollection 2018.

3.

Synthetic cannabinoids and endometrial stromal cell fate: dissimilar effects of JWH-122, UR-144 and WIN55,212-2.

Fonseca BM, Fernandes R, Almada M, Santos M, Carvalho F, Teixeira NA, Correia-da-Silva G.

Toxicology. 2018 Nov 28. pii: S0300-483X(18)30383-4. doi: 10.1016/j.tox.2018.11.006. [Epub ahead of print]

PMID:
30502353
4.

The Therapeutic Potential of Cannabinoids in Dermatology

Marks DH, Friedman A.

Skin Therapy Lett. 2018 Nov;23(6):1-5.

5.

Cannabis Therapeutics and the Future of Neurology.

Russo EB.

Front Integr Neurosci. 2018 Oct 18;12:51. doi: 10.3389/fnint.2018.00051. eCollection 2018.

6.

A Survey of Cannabis Acute Effects and Withdrawal Symptoms: Differential Responses Across User Types and Age.

Sexton M, Cuttler C, Mischley LK.

J Altern Complement Med. 2018 Oct 31. doi: 10.1089/acm.2018.0319. [Epub ahead of print]

PMID:
30383388
7.

Regulatory Status of Cannabidiol in the United States: A Perspective.

Corroon J, Kight R.

Cannabis Cannabinoid Res. 2018 Sep 27;3(1):190-194. doi: 10.1089/can.2018.0030. eCollection 2018.

8.

New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders.

Scherma M, Masia P, Deidda M, Fratta W, Tanda G, Fadda P.

Medicines (Basel). 2018 Oct 2;5(4). pii: E107. doi: 10.3390/medicines5040107. Review.

9.

A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis.

Berman P, Futoran K, Lewitus GM, Mukha D, Benami M, Shlomi T, Meiri D.

Sci Rep. 2018 Sep 24;8(1):14280. doi: 10.1038/s41598-018-32651-4.

10.

Inhibitory effects of cannabidiol on voltage-dependent sodium currents.

Ghovanloo MR, Shuart NG, Mezeyova J, Dean RA, Ruben PC, Goodchild SJ.

J Biol Chem. 2018 Oct 26;293(43):16546-16558. doi: 10.1074/jbc.RA118.004929. Epub 2018 Sep 14.

11.

Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history.

Bonini SA, Premoli M, Tambaro S, Kumar A, Maccarinelli G, Memo M, Mastinu A.

J Ethnopharmacol. 2018 Dec 5;227:300-315. doi: 10.1016/j.jep.2018.09.004. Epub 2018 Sep 8. Review.

PMID:
30205181
12.

Understanding the endocannabinoid system as a modulator of the trigeminal pain response to concussion.

Elliott MB, Ward SJ, Abood ME, Tuma RF, Jallo JI.

Concussion. 2017 Oct 4;2(4):CNC49. doi: 10.2217/cnc-2017-0010. eCollection 2017 Dec. Review.

13.

Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1-CB2 heteroreceptor complexes.

Navarro G, Reyes-Resina I, Rivas-Santisteban R, Sánchez de Medina V, Morales P, Casano S, Ferreiro-Vera C, Lillo A, Aguinaga D, Jagerovic N, Nadal X, Franco R.

Biochem Pharmacol. 2018 Nov;157:148-158. doi: 10.1016/j.bcp.2018.08.046. Epub 2018 Sep 6.

PMID:
30194918
14.

Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches.

Bonn-Miller MO, ElSohly MA, Loflin MJE, Chandra S, Vandrey R.

Int Rev Psychiatry. 2018 Jun;30(3):277-284. doi: 10.1080/09540261.2018.1474730.

PMID:
30179534
15.

Cannabinoids in cancer treatment: Therapeutic potential and legislation.

Dariš B, Tancer Verboten M, Knez Ž, Ferk P.

Bosn J Basic Med Sci. 2018 Sep 2. doi: 10.17305/bjbms.2018.3532. [Epub ahead of print] Review.

16.

Δ9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6.

Janssens A, Silvestri C, Martella A, Vanoevelen JM, Di Marzo V, Voets T.

Pharmacol Res. 2018 Oct;136:83-89. doi: 10.1016/j.phrs.2018.08.021. Epub 2018 Aug 28.

PMID:
30170189
17.

The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders.

Río CD, Millán E, García V, Appendino G, DeMesa J, Muñoz E.

Biochem Pharmacol. 2018 Nov;157:122-133. doi: 10.1016/j.bcp.2018.08.022. Epub 2018 Aug 20. Review.

PMID:
30138623
18.

Pharmacological treatment for REM sleep behavior disorder in Parkinson disease and related conditions: A scoping review.

de Almeida CMO, Pachito DV, Sobreira-Neto MA, Tumas V, Eckeli AL.

J Neurol Sci. 2018 Oct 15;393:63-68. doi: 10.1016/j.jns.2018.08.008. Epub 2018 Aug 10. Review.

PMID:
30118919
19.

Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis.

Rodríguez-Cueto C, Santos-García I, García-Toscano L, Espejo-Porras F, Bellido M, Fernández-Ruiz J, Muñoz E, de Lago E.

Biochem Pharmacol. 2018 Nov;157:217-226. doi: 10.1016/j.bcp.2018.07.049. Epub 2018 Aug 1.

PMID:
30076846
20.

Proteomics and Lipidomics in the Elucidation of Endocannabinoid Signaling in Healthy and Schizophrenia Brains.

Seabra G, Falvella ACB, Guest PC, Martins-de-Souza D, de Almeida V.

Proteomics. 2018 Sep;18(18):e1700270. doi: 10.1002/pmic.201700270. Epub 2018 Aug 20. Review.

PMID:
30070429

Supplemental Content

Loading ...
Support Center